申请人:The Wellcome Foundation Ltd.
公开号:US04423242A1
公开(公告)日:1983-12-27
Compounds of the general formula ##STR1## wherein Ph is a phenyl group which is optionally substituted by one or more substituents selected from halo (i.e. fluoro, chloro, bromo or iodo), C.sub.1-4 alkyl, amino, C.sub.1-4 alkylamino, di-C.sub.1-4 alkylamino, nitro, sulphonyl, aminosulphonyl, trihalomethyl, carboxy, C.sub.1-4 alkoxycarbonyl, amido, C.sub.1-4 alkylamido C.sub.1-4 alkoxy, C.sub.2-4 alkenyl, cyano, aminomethyl or methylsulphonyl; R.sup.a and R.sup.b, which may be the same or different, each represents a hydrogen or alkali metal (e.g. sodium or lithium) atom or a C.sub.1-4 (e.g. ethyl) group; m is 0 or 1; Y is a group of formula: --NH--CH.sub.2 --CO-- or a group of formula: ##STR2## where R.sup.1 is hydrogen or methyl; R.sup.2 is alkyl of 1 to 3 carbon atoms or is methylthiomethyl; and Z is --OR.sup.3 or --NR.sup.4 R.sup.5 where R.sup.3, R.sup.4 and R.sup.5 are each hydrogen or alkyl of 1 to 4 carbon atoms (i.e. methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, or t-butyl) and R.sup.3 can further be phenylalkyl having 1 to 3 carbon atoms in the alkylene moiety thereof, or phenyl; and basic salts thereof. These compounds have an advantageous enkephalinase inhibitory activity which renders the compounds useful in medical therapy, e.g. to prolong and/or potentiate in a mammal, the effects of endogenous or exogenous enkephalins. The latter includes synthetic enkepalin analogues.
通式为##STR1##的化合物,其中Ph是苯基,可以选择性地由卤素(即氟、氯、溴或碘)、C.sub.1-4烷基、氨基、C.sub.1-4烷基氨基、二-C.sub.1-4烷基氨基、硝基、磺酰基、氨基磺酰基、三卤甲基、羧基、C.sub.1-4烷氧基羰基、酰胺基、C.sub.1-4烷基酰胺基、C.sub.1-4烷氧基、C.sub.2-4烯基、氰基、氨甲基或甲基磺酰基取代的苯基;R.sup.a和R.sup.b可以相同也可以不同,分别代表氢或碱金属(例如钠或锂)原子或C.sub.1-4(例如乙基)基团;m为0或1;Y是式:--NH--CH.sub.2 --CO--或式:##STR2## 其中R.sup.1为氢或甲基;R.sup.2为1至3碳原子的烷基或甲基硫代甲基;Z为--OR.sup.3或--NR.sup.4 R.sup.5,其中R.sup.3、R.sup.4和R.sup.5分别为氢或1至4碳原子的烷基(即甲基、乙基、正丙基、异丙基、正丁基、异丁基或叔丁基),并且R.sup.3可以进一步为含有1至3碳原子的烷基的苯基烷基,或苯基;以及其碱性盐。这些化合物具有有利的脑内啡酶抑制活性,使这些化合物在医学治疗中有用,例如在哺乳动物中延长和/或增强内源性或外源性脑内啡酪肽的作用。后者包括合成的脑内啡肽类似物。